Cooley’s attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has 900 lawyers across 12 offices in the United States, China and Europe. Cooley's antitrust & competition team is recognized as one of the top-tier practices in the area of antitrust by Legal 500, Chambers USA and Global Competition Review. We handle all aspects of antitrust and competition law matters – including counseling, litigation, agency representation and arbitration services – for Fortune 500 corporations, as well as growing companies.
Paul, Weiss (www.paulweiss.com) is a firm of more than 1,000 lawyers with diverse backgrounds, personalities, ideas and interests who provide innovative and effective solutions to our clients’ most complex legal and business challenges. We take great pride in representing the world’s leading companies in their critical legal matters and most significant business transactions, as well as individuals and organizations in need of pro bono assistance.
OnPoint Analytics is an economic, statistical and financial consulting firm located in the San Francisco Bay Area. It is known for its intensive data analyses in complex litigation, including antitrust and other forms of unfair competition, intellectual property, and breach of contract. Much of OnPoint’s work involves the health care industry, spanning network creation, premium pricing, and reimbursement practices. OnPoint has a dedicated team addressing pharmaceutical products and markets. Its drug cases include antitrust class actions, patent litigation, injunction proceedings, and a wide range of competition disputes including interference with contract to eliminate competitor products.
Howard Morse is a Washington, DC-based partner in Cooley's Antitrust & Competition practice group. He represents businesses before the Department of Justice, Federal Trade Commission, and state attorneys general in investigations of mergers, acquisitions and joint ventures, as well as alleged monopolization, restraint of trade and unfair and deceptive practices. Howard has been at the forefront of applying antitrust law to the high-tech sector and the intersection of antitrust and intellectual property law, and regularly represents clients in technology, life sciences and other high-tech industries.
Before joining Cooley, Howard served for 10 years at the FTC, where he was Assistant Director of the Bureau of Competition and responsible for more than 50 enforcement actions. In the private sector, Howard has recently represented Rovi in its $1.1 billion acquisition of Tivo, combining two media and entertainment innovators, and Zeltiq in its $2.5 billion sale to Allergan, combining leaders in medical aesthetics.
A partner in the Antitrust Group, Andy Forman focuses his practice on counseling clients in a wide range of antitrust matters, with an emphasis on mergers and acquisitions, joint ventures and investigations by the U.S. Department of Justice and U.S. Federal Trade Commission. Throughout his career, Andy has represented numerous leading companies including Cigna, Eli Lilly & Company, Goodyear Tire and Rubber Co., Microsoft Corporation, Pfizer Inc., Salix Pharmaceuticals, Ltd., Smith & Nephew and US Airways Inc.
Andy previously worked for the FTC’s Bureau of Competition (Mergers I), where he helped lead antitrust investigations in large mergers and acquisitions in the pharmaceutical, medical device, consumer products, industrial products and aircraft components industries. He has been recognized by The Legal 500, Benchmark Litigation and The Best Lawyers in America. Andy received a J.D. from Georgetown University Law Center and a B.A. from Washington University. He has worked on multiple matters that won the Global Competition Review’s antitrust matter of the year.
Laura Craft is co-founder of OnPoint Analytics, Inc., an economic and statistical consulting firm specializing in antitrust, pharmaceutical industry, health care, class action and intellectual property litigation. She has overseen the development of expert testimony in more than sixty pharmaceutical industry cases, spanning almost all major classes of drug treatments. Her recent publications include the book Empirical Challenges in Pharma Litigation. Recent antitrust cases in which she has served as testifying expert include In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (End Payor Actions); In re: Niaspan Antitrust Litigation (End Payor Actions); In re: Loestrin Antitrust Litigation (End Payor Actions); and In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation.